LBIO Lion Biotechnologies Inc

Scott+Scott, Attorneys at Law, LLP Reminds Investors of Upcoming Deadline to File Lead Plaintiff Papers in Lion Biotechnologies, Inc. (LBIO) Securities Case

Scott+Scott, Attorneys at Law, LLP (“Scott+Scott”), a national shareholder and consumer rights litigation firm, reminds investors that June 13, 2017 is the last day to file lead plaintiff papers in the securities lawsuit against Lion Biotechnologies, Inc. (“Lion” or the “Company”) (NASDAQ:LBIO). The class action is on behalf of a class consisting of all persons who purchased Lion common stock between November 14, 2013 and April 10, 2017, both dates inclusive (the “Class Period”). Lion investors are encouraged to contact Scott+Scott toll free at (844) 818-6982 for more information.

Lion focuses on developing and commercializing cancer immunotherapy products. Lion shares are traded on the NASDAQ stock exchange under the ticker symbol “LBIO.”

The lawsuit alleges that throughout the Class Period, Defendants made false and/or misleading statements and/or failed to disclose that: (1) Lion Biotechnologies, through its former CEO Manish Singh, engaged in a scheme to mislead investors by commissioning over 10 internet publications and 20 widely distributed emails promoting Lion Biotechnologies to potential investors that purported to be independent from the company when, in fact, they were paid promotions; (2) former CEO Singh engaged a stock promotion firm to pay writers to publish articles about Lion Biotechnologies on investment websites as well as to coordinate the distribution of articles to thousands of electronic mailboxes; (3) former CEO Singh actively participated in the promotional work for Lion Biotechnologies and understood that the promotion firm was using writers who would not disclose that Lion Biotechnologies was indirectly compensating them for their publications; and (4) as a result, defendants’ public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

What You Can Do

If you purchased Lion shares, you may have legal claims against the Company. If you want to discuss filing lead plaintiff papers, or have questions about your legal rights, please contact attorney Joseph Pettigrew at (844) 818-6982, or at [email protected].

About Scott+Scott, Attorneys at Law, LLP

Scott+Scott has significant experience prosecuting major securities, antitrust, and employee retirement plan actions throughout the United States. The firm represents pension funds, foundations, individuals, and other entities worldwide with offices in New York, London, Connecticut, California, and Ohio.

EN
09/05/2017

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Lion Biotechnologies Inc

 PRESS RELEASE

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing...

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) SAN CARLOS, Calif., Jan. 16, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (“TIL”) therapies for patients with cancer, today announced that on January 15, 2026 (the “Date of Grant”), the Company approved the grant of inducement stock options covering an aggregate of 97,710 shares of Iovance’s common stock to 17 new, non-executive e...

 PRESS RELEASE

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing...

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) SAN CARLOS, Calif., Dec. 19, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (“TIL”) therapies for patients with cancer, today announced that on December 18, 2025 (the “Date of Grant”), the Company approved the grant of inducement stock options covering an aggregate of 43,150 shares of Iovance’s common stock to four new, non-executiv...

 PRESS RELEASE

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing...

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) SAN CARLOS, Calif., Nov. 21, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (“TIL”) therapies for patients with cancer, today announced that on November 20, 2025 (the “Date of Grant”), the Company approved the grant of inducement stock options covering an aggregate of 164,900 shares of Iovance’s common stock to 11 new, non-executive...

 PRESS RELEASE

Iovance Biotherapeutics Highlights Business Achievements, Pipeline Mil...

Iovance Biotherapeutics Highlights Business Achievements, Pipeline Milestones, and Third Quarter 2025 Results Quarterly Revenue Growth of 13% to ~$68 Million  Gross Margin Increased to 43% on Improved Execution and Operational Efficiency Best-in-Class Clinical Profile for Lifileucel in Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC) with Median Duration of Response Not Reached after 25+ Months Follow Up SAN CARLOS, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, ...

 PRESS RELEASE

Iovance Biotherapeutics Reports Potential Best-in-Class Clinical Data ...

Iovance Biotherapeutics Reports Potential Best-in-Class Clinical Data for Lifileucel TIL Cell Therapy in Advanced Non-Small Cell Lung Cancer (NSCLC) 26% Objective Response Rate  Median Duration of Response Not Reached after 25 Months Follow Up Lifileucel Launch in Previously Treated Advanced NSCLC Expected in Second Half of 2027 SAN CARLOS, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch